Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.41 |
| ▸ | HMGCR | P04035 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22526118 | 1.00 | PAOX (0.43) | PAOXPTPN7HMGCRALDH1A1TDP1 | |
| SCHEMBL25468189 | 0.82 | PTPN7 (0.40) | PTPN7HMGCR | |
| SCHEMBL25110145 | 0.82 | PTPN7 (0.40) | PTPN7HMGCR | |
| SCHEMBL24765696 | 0.82 | PTPN7 (0.40) | PTPN7HMGCR | |
| SCHEMBL3817935 | 0.82 | PTPN7 (0.57) | PTPN7HMGCRALDH1A1TDP1RECQL | |
| SCHEMBL22526115 | 0.82 | PTPN7 (0.38) | PTPN7HMGCRALDH1A1TDP1RECQL | |
| SCHEMBL23945587 | 0.80 | PTPN7 (0.37) | PTPN7HMGCRALDH1A1TDP1RECQL | |
| SCHEMBL25122683 | 0.77 | PTPN7 (0.35) | PTPN7HMGCRALDH1A1TDP1RECQL | |
| SCHEMBL14369459 | 0.75 | PTPN7 (0.70) | PTPN7HMGCRALDH1A1TDP1RECQL | |
| SCHEMBL11210943 | 0.75 | PTPN7 (0.48) | PAOXPTPN7HMGCRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PAOX 1862/4885PTPN7 337/4885HMGCR 1374/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PAOX 153/4885PTPN7 3487/4885HMGCR 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.